Journal of Medical Economics

Papers
(The H4-Index of Journal of Medical Economics is 18. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)
ArticleCitations
Health outcomes and economic burden of hospitalized COVID-19 patients in the United States126
The Global South political economy of health financing and spending landscape – history and presence71
Economic value of vaccines to address the COVID-19 pandemic: a U.S. cost-effectiveness and budget impact analysis43
Iran, sanctions, and the COVID-19 crisis36
Evaluation of COVID-19 vaccine breakthrough infections among immunocompromised patients fully vaccinated with BNT162b235
How China controls the Covid-19 epidemic through public health expenditure and policy?31
Asian innovation in pharmaceutical and medical device industry – beyond tomorrow31
Economic and humanistic burden associated with noncommunicable diseases among adults with depression and anxiety in the United States23
Cost-utility analysis of normothermic liver perfusion with the OrganOx metra compared to static cold storage in the United Kingdom23
Total cost of testing for genomic alterations associated with next-generation sequencing versus polymerase chain reaction testing strategies among patients with metastatic non-small cell lung cancer22
Cost effectiveness of axicabtagene ciloleucel versus tisagenlecleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the United Sta22
Tezepelumab compared with other biologics for the treatment of severe asthma: a systematic review and indirect treatment comparison22
Economic implications of the modern treatment paradigm of glioblastoma: an analysis of global cost estimates and their utility for cost assessment21
Cost utility analysis of tisagenlecleucel vs salvage chemotherapy in the treatment of relapsed/refractory diffuse large B-cell lymphoma from Singapore’s healthcare system perspective20
Cost-effectiveness analysis of sintilimab + chemotherapy versus camrelizumab + chemotherapy for the treatment of first-line locally advanced or metastatic nonsquamous NSCLC in China20
Burden of Crohn’s disease in the United States: long-term healthcare and work-loss related costs20
The societal economic value of COVID-19 vaccines in the United States19
A US cost-minimization model comparing ravulizumab versus eculizumab for the treatment of atypical hemolytic uremic syndrome18
0.033545017242432